GBA Presents: THE GREEN MARKET

WHO NEEDS A GUMMY?- CDXS

Pfizer's Paxlovid forecast 'bodes well' for Codexis, says Benchmark 08:35 CDXS, PFE Benchmark analyst Robert Wasserman maintains a Buy rating and $45 price target on Codexis (CDXS) shares after customer and key partner Pfizer (PFE) reported Q4 results and offered some insight on their COVID-19 oral therapeutic Paxlovid. Sales of Codexis' performance enzymes for use in manufacturing Paxlovid were the company's largest revenue source in 2021, accounting for approximately 30% of sales, and Pfizer's guidance for sales of Paxlovid to rise to $22B this year "bodes well" for Codexis, Wasserman tells investors. He expects that if Pfizer's commentary yesterday holds true, that repeat sales to Pfizer by Codexis in 2022 could meet those of 2021, the analyst added.

>>>>>>>>>>>>>>> That last line concerns me....

$19 stk
 
Trust Stamp receives funding commitment for development of Medical QR Code » 08:34 IDAI


Aemetis signs agreement with Japan Airlines to supply 90M gallons of SAF 08:06 AMTX, JAPSY Aemetis (AMTX) announced that an offtake agreement has been signed with Japan Airlines (JAPSY) for 90M gallons of blended sustainable aviation fuel, SAF, to be delivered over the 7 year term of the agreement. The sustainable aviation fuel is expected to be produced by the Aemetis renewable jet/diesel plant under development on a 125 acre former U.S. Army Ammunition production plant site in Riverbank, California. The blended sustainable aviation fuel is scheduled to begin deliveries to JAL in 2025. "The use of sustainable aviation fuel by Japan Airlines is another step by the oneworld Alliance toward lowering the environmental impact of aviation," stated Eric McAfee, Chairman and CEO of Aemetis. "Our supply of SAF to the San Francisco International Airport is supported by the California Low Carbon Fuel Standard, creating new investment and jobs in disadvantaged minority communities in the state."
 
You must log in or register to reply here.
Back
Top